Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Genetics

Is Aicardi-Goutières Syndrome Caused by a Virus?

At a Glance

Aicardi-Goutières syndrome (AGS) is a purely genetic condition, not a viral TORCH infection caught during pregnancy. Genetic mutations cause the infant's immune system to mistakenly attack its own cells, creating brain inflammation that perfectly mimics a viral infection.

No, Aicardi-Goutières syndrome (AGS) is not caused by a virus you caught during pregnancy. It is an entirely genetic condition [1].

It is incredibly common for mothers of children with AGS to carry deep guilt, wondering if they ate something wrong, cleaned a litter box, or caught a cold that caused their child’s condition. If you have been carrying this burden, you can let it go. AGS is not an infection [2], and there is nothing you did to cause it.

The confusion usually stems from how AGS looks on medical scans and early physical exams. When doctors first look at the brain MRI of a child with AGS, they often suspect a TORCH infection [2]. TORCH is an acronym for a group of viral and parasitic infections (like Toxoplasmosis, Rubella, Cytomegalovirus, and Herpes) that can pass from a mother to a fetus during pregnancy. Both TORCH infections and AGS cause identical patterns of calcium buildup (calcifications) in the brain [3][4]. They can also cause similar physical signs in a newborn, such as an enlarged liver or spleen, and skin rashes [5].

Because the damage looks so remarkably similar, doctors refer to AGS as a pseudo-TORCH syndrome [2][5]. This means it mimics a congenital viral infection, but it is actually a genetic condition [6][7].

Why Does a Genetic Condition Look Like a Virus?

The reason AGS perfectly mimics a viral infection is fascinating but devastating: it tricks the baby’s own body into thinking a virus is present when there isn’t one [8][9].

Our cells constantly produce and recycle their own genetic material (DNA and RNA). In a healthy body, specific genes produce “clean-up” enzymes that clear out this old, recycled material. In a child with AGS, a mutation in one of these genes (such as TREX1, RNASEH2B, or others) prevents these clean-up enzymes from working properly [1][10][11].

When the body’s own leftover DNA and RNA build up inside the cells, the immune system makes a crucial mistake. It sees this buildup, assumes the cells have been invaded by a virus, and launches a massive immune attack [8][9][12].

The “False Alarm” Immune Response

When the immune system sounds this false alarm, it produces a flood of an inflammatory protein called interferon [13]. Interferon is the chemical our bodies use to fight off severe viral infections. In AGS, the body is constantly fighting a ghost virus [14][15].

This chronic, high-alert immune response—specifically the overproduction of type I interferon—causes the widespread inflammation and calcium buildup in the brain that doctors see on MRI scans [13][16][17]. Over time, this brain inflammation leads to the physical symptoms you might see in your child, such as severe developmental delays, muscle stiffness (spasticity), or uncontrollable movements [18][19]. The brain is being damaged by the body’s own immune response, not by an external virus [20].

Moving Forward Without Guilt

If your child’s doctors originally suspected a TORCH infection, they were doing their job properly by following the visual evidence on the MRI [3]. However, to definitively diagnose AGS, doctors must run blood tests (called TORCH titers) to prove there is no actual infection [21][6], followed by genetic testing to find the mutated gene [18][19].

AGS is a genetic condition [1]. Most often, it occurs because both parents silently carried a hidden gene mutation, with absolutely no way of knowing they had it. In other cases, it happens as a spontaneous, new change (called a de novo mutation) in the baby’s DNA [22].

Please do not replace the guilt of “catching a virus” with the guilt of “passing on a gene.” We all carry silent genetic mutations. AGS is simply a biological miscommunication written into your child’s cells. It is not a consequence of an illness you contracted, and it could not have been prevented by any lifestyle choice or standard prenatal care. When you are ready, speaking with a genetic counselor can help you fully understand your child’s specific genetic results and what they might mean if you plan to expand your family.

Common questions in this guide

Is Aicardi-Goutières syndrome caused by something I did during pregnancy?
No, Aicardi-Goutières syndrome is an entirely genetic condition. It is not caused by a virus, an infection, or any lifestyle choices made during pregnancy, so there is no reason for parents to feel guilty.
Why did doctors initially suspect a TORCH infection for my child?
AGS causes brain calcifications and physical signs that look identical to TORCH viral infections on MRI scans and newborn exams. This is why doctors often call AGS a pseudo-TORCH syndrome before genetic testing is complete.
How does a genetic condition mimic a viral infection?
In AGS, genetic mutations prevent cells from cleaning up their own recycled DNA and RNA. The infant's immune system mistakes this cellular buildup for an invading virus and launches a massive, damaging inflammatory response.
How do doctors officially diagnose AGS instead of a viral infection?
Doctors use blood tests called TORCH titers to prove there is no active viral infection. They then perform genetic testing to identify the specific gene mutation, such as TREX1 or RNASEH2B, causing the condition.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which specific genetic mutation (such as TREX1, RNASEH2B, or others) is causing my child's AGS, and was it inherited or a spontaneous change?
  2. 2.Since my child's body is overproducing interferon due to this 'false alarm', are they a candidate for treatments like JAK inhibitors that help block this inflammatory pathway?
  3. 3.Can you provide a referral to a genetic counselor so our family can better understand the recurrence risk if we decide to have more children?
  4. 4.What baseline evaluations do we need to monitor the current level of inflammation or calcifications in my child's brain?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

What Do Aicardi-Goutières Syndrome Chilblains Look Like?Why is a Fever a Medical Emergency on JAK Inhibitors?What is the Aicardi-Goutières Syndrome Life Expectancy?Why is Aicardi-Goutières Misdiagnosed as Cerebral Palsy?What Organs Does Aicardi-Goutières Syndrome (AGS) Affect?Does Aicardi-Goutières Syndrome Get Worse Over Time?Will Our Next Child Have Aicardi-Goutières Syndrome?What Happens If You Miss a JAK Inhibitor Dose for AGS?What Is the Interferon Signature Test for AGS?

References

References (22)
  1. 1

    Aicardi-Goutières syndrome: A monogenic type I interferonopathy.

    Liu A, Ying S

    Scandinavian journal of immunology 2023; (98(4)):e13314 doi:10.1111/sji.13314.

    PMID: 37515439
  2. 2

    A Novel Familial Case Report of Genetic Syndrome Mimicking Congenital TORCH infections; Pseudo-TORCH Syndrome 2.

    Sehrish I, Sunitha T, Srilekha A, et al.

    Journal of reproduction & infertility 2022; (23(2)):135-138 doi:10.18502/jri.v23i2.8999.

    PMID: 36043132
  3. 3

    Aicardi-Goutières syndrome (AGS): recurrent fetal cardiomyopathy and pseudo-TORCH syndrome.

    Panigrahy N, Bakhru S, Lingappa L, Chirla D

    BMJ case reports 2022; (15(12)) doi:10.1136/bcr-2022-249192.

    PMID: 36581356
  4. 4

    USP18 gene mutation associated with recurrent encephalopathy, intracranial calcification, and microcephaly: case report, long-term follow-up, and literature review.

    Gowda VK, Srinivasan VM, Varghese A, et al.

    Clinical dysmorphology 2025; doi:10.1097/MCD.0000000000000538.

    PMID: 41198138
  5. 5

    USP18 Deficiency Presenting as Severe Neonatal Encephalopathy: A Case Report and Review of Pseudo-TORCH Syndromes.

    Alattas A, Alsamnan M

    Cureus 2025; (17(9)):e91952 doi:10.7759/cureus.91952.

    PMID: 40937018
  6. 6

    Intracranial calcifications in childhood: Part 2.

    Gonçalves FG, Caschera L, Teixeira SR, et al.

    Pediatric radiology 2020; (50(10)):1448-1475 doi:10.1007/s00247-020-04716-y.

    PMID: 32642802
  7. 7

    Microglial Interferon Signaling and White Matter.

    McDonough A, Lee RV, Weinstein JR

    Neurochemical research 2017; (42(9)):2625-2638 doi:10.1007/s11064-017-2307-8.

    PMID: 28540600
  8. 8

    ADAR1 entraps sinister cellular dsRNAs, thresholding antiviral responses.

    Keegan LP, Vukić D, O'Connell MA

    Trends in immunology 2021; (42(11)):953-955 doi:10.1016/j.it.2021.09.013.

    PMID: 34642093
  9. 9

    RNase H2 catalytic core Aicardi-Goutières syndrome-related mutant invokes cGAS-STING innate immune-sensing pathway in mice.

    Pokatayev V, Hasin N, Chon H, et al.

    The Journal of experimental medicine 2016; (213(3)):329-36 doi:10.1084/jem.20151464.

    PMID: 26880576
  10. 10

    Aicardi-Goutières Syndrome Type 1: A Novel Missense Variant and Review of the Mutational Spectrum.

    Tasharrofi B, Karimzadeh P, Asadollahi M, et al.

    Iranian journal of child neurology 2024; (18(3)):117-129 doi:10.22037/ijcn.v18i3.43274.

    PMID: 38988838
  11. 11

    Baricitinib Treatment in RNU7-1-Associated Aicardi-Goutières Syndrome in a South African Child: A Case Report.

    Spracklen TF, Akhalwaya S, Ackermann S, et al.

    American journal of medical genetics. Part A 2025; (197(5)):e63978 doi:10.1002/ajmg.a.63978.

    PMID: 39748568
  12. 12

    Genome instability independent of type I interferon signaling drives neuropathology caused by impaired ribonucleotide excision repair.

    Aditi , Downing SM, Schreiner PA, et al.

    Neuron 2021; (109(24)):3962-3979.e6 doi:10.1016/j.neuron.2021.09.040.

    PMID: 34655526
  13. 13

    Clinical spectrum and currently available treatment of type I interferonopathy Aicardi-Goutières syndrome.

    Dell'Isola GB, Dini G, Culpepper KL, et al.

    World journal of pediatrics : WJP 2023; (19(7)):635-643 doi:10.1007/s12519-022-00679-2.

    PMID: 36650407
  14. 14

    Human USP18 deficiency underlies type 1 interferonopathy leading to severe pseudo-TORCH syndrome.

    Meuwissen ME, Schot R, Buta S, et al.

    The Journal of experimental medicine 2016; (213(7)):1163-74 doi:10.1084/jem.20151529.

    PMID: 27325888
  15. 15

    Inborn Errors of Immunity With Fetal or Perinatal Clinical Manifestations.

    Carneiro-Sampaio M, de Jesus AA, Bando SY, Moreira-Filho CA

    Frontiers in pediatrics 2022; (10()):891343 doi:10.3389/fped.2022.891343.

    PMID: 35601409
  16. 16

    The brain microvasculature is a primary mediator of interferon-α neurotoxicity in human cerebral interferonopathies.

    Viengkhou B, Hayashida E, McGlasson S, et al.

    Immunity 2024; (57(7)):1696-1709.e10 doi:10.1016/j.immuni.2024.05.017.

    PMID: 38878770
  17. 17

    Interferon-Stimulated Gene Expression as a Preferred Biomarker for Disease Activity in Aicardi-Goutières Syndrome.

    Wang BX, Grover SA, Kannu P, et al.

    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2017; (37(4)):147-152 doi:10.1089/jir.2016.0117.

    PMID: 28387595
  18. 18

    Diagnosis of Aicardi-Goutières Syndrome in Adults: A Case Series.

    Videira G, Malaquias MJ, Laranjinha I, et al.

    Movement disorders clinical practice 2020; (7(3)):303-307 doi:10.1002/mdc3.12903.

    PMID: 32258229
  19. 19

    SIGLEC1 (CD169) as a potential diagnostical screening marker for monogenic interferonopathies.

    Orak B, Ngoumou G, Ebstein F, et al.

    Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 2021; (32(3)):621-625 doi:10.1111/pai.13400.

    PMID: 33099809
  20. 20

    Efficacy of Baricitinib in the Treatment of Chilblains Associated With Aicardi-Goutières Syndrome, a Type I Interferonopathy.

    Meesilpavikkai K, Dik WA, Schrijver B, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2019; (71(5)):829-831 doi:10.1002/art.40805.

    PMID: 30666809
  21. 21

    A Case Report and Literature Review of Pseudo-TORCH Syndrome Type 2 (PTORCH2).

    Misk RA, Qawasme L, Abunejma FM, et al.

    Case reports in pediatrics 2022; (2022()):3555532 doi:10.1155/2022/3555532.

    PMID: 36317064
  22. 22

    The c.529G>A (p.Ala177Thr) RNASEH2B Gene Pathogenic Variant as a First-Line Genetic Test for Aicardi-Goutières Syndrome: A Case Series of Four Moroccan Families.

    Ouhenach M, Nada A, Lyahyai J, Sefiani A

    American journal of medical genetics. Part A 2025; (197(6)):e63997 doi:10.1002/ajmg.a.63997.

    PMID: 39890436

This page provides educational information about the genetic causes of Aicardi-Goutières syndrome. Always consult a genetic counselor or pediatric neurologist regarding your child's specific diagnosis and medical care.

Get notified when new evidence is published on Aicardi-Goutières syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.